Skip to main content
. 2023 Sep 14;9(9):1835–1845. doi: 10.1021/acscentsci.3c00625

Figure 1.

Figure 1

Engineered anthrax proteins for targeted vaccine delivery into cross-presenting dendritic cells. (A) Designs of the engineered components: triple mutant protective antigen (mPAC), which enables side-chain bioconjugation and ablates binding to native anthrax receptors; single-chain variable fragment (scFv), which recognizes the XCR1 receptor; and a linker peptide (dotted line), which connects the scFv and mPAC. (B) Envisioned mechanism of translocation for scFv-mPAC (scFv-mPAC83), which exhibits recognition of the XCR1 receptor, proteolytic cleavage (scFv-mPAC63), oligomerization (scFv-mPAC)7, and cytosolic delivery of the N-terminus of lethal factor (LFN) with an appended antigen peptide (red).